Adma Biologics (ADMA) shares rallied 7.8% in the last trading session to close at $20.91. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 5.3% gain over the past four weeks.
Strong fundamentals, buoyed by broader market optimism, drove this rally for ADMA Biologics.
This infectious disease drug developer is expected to post quarterly earnings of $0.16 per share in its upcoming report, which represents a year-over-year change of +100%. Revenues are expected to be $119.1 million, up 45.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Adma Biologics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ADMA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Adma Biologics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Blueprint Medicines (BPMC), finished the last trading session 2.1% higher at $82.53. BPMC has returned -9.8% over the past month.
For Blueprint Medicines
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADMA Biologics Inc (ADMA): Free Stock Analysis Report Blueprint Medicines Corporation (BPMC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
